Drugs / RTX-321
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04672980 | Apr 2021 → Nov 2022 | anal carcinoma, cervical cancer, head and neck cancer | Rubius Therapeutics | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RTX-321 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04672980 ↗ |
| Modality | Cell therapy | “RTX-321 is a cellular therapy” NCT04672980 ↗ |
| Route | Intravenous | “RTX-321 administered intravenously” NCT04672980 ↗ |